Atossa Genetics (ATOS) Expected to Announce Earnings on Wednesday

Atossa Genetics (NASDAQ:ATOS – Get Free Report) is anticipated to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.86) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:30 AM ET.

Atossa Genetics (NASDAQ:ATOS – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.07. On average, analysts expect Atossa Genetics to post ($3.75) EPS for the current fiscal year and ($2.78) EPS for the next fiscal year.

Atossa Genetics Stock Up 0.5%

Shares of NASDAQ ATOS opened at $2.13 on Tuesday. The firm’s 50 day simple moving average is $2.37 and its 200-day simple moving average is $3.78. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $14.85.

Analysts Set New Price Targets

A number of research analysts have weighed in on ATOS shares. Wall Street Zen raised shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Atossa Genetics in a research note on Tuesday, September 8th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.33.

View Our Latest Analysis on Atossa Genetics

About Atossa Genetics

(Get Free Report)

Atossa Genetics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Read More

Earnings History for Atossa Genetics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.